Learning Objectives:

  • To review the role of alpha synuclein in the pathogenesis of Parkinson’s disease.
  • To review various potential approaches targeting alpha synuclein as disease modifying therapies for Parkinson’s disease.

To summarize the current status of active clinical trials targeting alpha synuclein

Session date: 
12/03/2020 - 7:30am to 8:30am CST
United States
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Anthony Lang, MD